Effects of protein and omega-3 supplementation, provided during regular dialysis sessions, on nutritional and inflammatory indices in hemodialysis patients

Vascular Health and Risk Management

Volumn 8, Issue 1, 2012, Pages 187-195

  Mat Daud, Zulfitri A ^a   Tubie, Boniface ^b   Adams, Judy ^b   Quainton, Tracey ^b   Osia, Robert ^b   Tubie, Sharon ^b   Kaur, Deepinder ^a   Khosla, Pramod ^a   Sheyman, Marina ^b  

^a WAYNE STATE UNIVERSITY   (United States)

^b Great Lake Dialysis Clinic   (United States)

Author keywords

Hemodialysis; Inflammation; Nutritional status; Protein and omega 3 supplementation

Indexed keywords

C REACTIVE PROTEIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; NATURAL PRODUCTS AND THEIR SYNTHETIC DERIVATIVES; OMEGA 3 FATTY ACID; PLACEBO; PROTEINEX; SERUM ALBUMIN; UNCLASSIFIED DRUG; AUTACOID; BIOLOGICAL MARKER; DOCOSAHEXAENOIC ACID; ICOSAPENTAENOIC ACID; LIPID;

ADULT; ALBUMIN BLOOD LEVEL; ARTICLE; CARDIOVASCULAR DISEASE; CLINICAL EFFECTIVENESS; CONTROLLED STUDY; DIABETES MELLITUS; DIET SUPPLEMENTATION; DISEASE ASSOCIATION; DRUG EFFECT; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; FEASIBILITY STUDY; FEMALE; HEMODIALYSIS; HUMAN; HYPOALBUMINEMIA; INFECTION; INFLAMMATION; LIPID BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; NUTRITIONAL ASSESSMENT; NUTRITIONAL DEFICIENCY; OUTCOME ASSESSMENT; PATIENT ASSESSMENT; PATIENT COMPLIANCE; RANDOMIZED CONTROLLED TRIAL; TREATMENT DURATION; AGED; BEVERAGE; BLOOD; BODY MASS; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; DIRECTLY OBSERVED THERAPY; IMMUNOLOGY; KIDNEY DISEASE; MALNUTRITION; METABOLISM; MICROCAPSULE; MIDDLE AGED; NUTRITIONAL STATUS; PATHOPHYSIOLOGY; PILOT STUDY; PROTEIN INTAKE; RENAL REPLACEMENT THERAPY; TIME; TREATMENT OUTCOME; UNITED STATES;

AGED; BEVERAGES; BIOLOGICAL MARKERS; BODY MASS INDEX; C-REACTIVE PROTEIN; CAPSULES; DIETARY PROTEINS; DIETARY SUPPLEMENTS; DIRECTLY OBSERVED THERAPY; DOCOSAHEXAENOIC ACIDS; EICOSAPENTAENOIC ACID; FATTY ACIDS, OMEGA-3; FEASIBILITY STUDIES; FEMALE; HUMANS; INFLAMMATION; INFLAMMATION MEDIATORS; KIDNEY DISEASES; LIPIDS; MALE; MALNUTRITION; MICHIGAN; MIDDLE AGED; NF-KAPPA B; NUTRITIONAL STATUS; PATIENT COMPLIANCE; PILOT PROJECTS; RENAL DIALYSIS; SERUM ALBUMIN; TIME FACTORS; TREATMENT OUTCOME;

EID: 84863202696     PISSN: 11766344     EISSN: 11782048     Source Type: Journal    
DOI: 10.2147/VHRM.S28739     Document Type: Article

References (46)

1. Giray B, Kan E, Bali M, Hincal F, Basaran N. The effect of vitamin E supplementation on antioxidant enzyme activities and lipid peroxidation levels in hemodialysis patients. Clin Chim Acta. 2003;338(1-2):91-98.
2. Stenvinkel P, Heimburger O, Paultre F, et al. Strong association between malnutrition, inflammation, and atherosclerosis in chronic renal failure. Kidney Int. 1999;55(5):1899-1911.
3. Kalantar-Zadeh K, Ikizler TA, Block G, Avram MM, Kopple JD. Malnutrition-inflammation complex syndrome in dialysis patients: causes and consequences. Am J Kidney Dis. 2003;42(5):864-881.
4. Stratton RJ, Bircher G, Fouque D, et al. Multinutrient oral supplements and tube feeding in maintenance dialysis: a systematic review and meta-analysis. Am J Kidney Dis. 2005;46(3):387-405.
5. Cano N. Nutritional supplementation in adult patients on hemodialysis. J Ren Nutr. 2007;17(1):103-105.
6. Meade A. Protein supplementation with sports protein bars in renal patients. J Ren Nutr. 2007;17(3):214-217.
7. Razeghi E, Omati H, Maziar S, Khashayar P, Mahdavi-Mazdeh M. Chronic inflammation increases risk in hemodialysis patients. Saudi J Kidney Dis Transpl. 2008;19(5):785-789.
8. Kalantar-Zadeh K, Braglia A, Chow J, et al. An anti-inflammatory and antioxidant nutritional supplement for hypoalbuminemic hemodialysis patients: a pilot/feasibility study. J Ren Nutr. 2005;15(3):318-331.
9. Harris WS, Park Y, Isley WL. Cardiovascular disease and long-chain omega-3 fatty acids. Curr Opin Lipidol. 2003;14(1):9-14.
10. Hu FB, Bronner L, Willett WC, et al. Fish and omega-3 fatty acid intake and risk of coronary heart disease in women. JAMA. 2002;287(14):1815-1821.
11. Egert S, Stehle P. Impact of n-3 fatty acids on endothelial function: results from human interventions studies. Curr Opin Clin Nutr Metab Care. 2011;14(2):121-131.
12. Olza J, Mesa MD, Aguilera CM, et al. Influence of an eicosapentaenoic and docosahexaenoic acid-enriched enteral nutrition formula on plasma fatty acid composition and biomarkers of insulin resistance in the elderly. Clin Nutr. 2010;29(1):31-37.
13. Noori N, Dukkipati R, Kovesdy CP, et al. Dietary omega-3 fatty acid, ratio of omega-6 to omega-3 Intake, inflammation, and survival in longterm hemodialysis patients. Am J Kidney Dis. 2011;58(2):248-256.
14. Madsen T, Christensen JH, Svensson M, Witt PM, Toft E, Schmidt EB. Marine n-3 polyunsaturated fatty acids in patients with end-stage renal failure and in subjects without kidney disease: a comparative study. J Ren Nutr. 2011;21(2):169-175.
15. Friedman A, Moe S. Review of the effects of omega-3 supplementation in dialysis patients. Clin J Am Soc Nephrol. 2006;1(2):182-192.
16. Griffith S. A review of the factors associated with patient compliance and the taking of prescribed medicines. Br J Gen Pract. 1990;40(332):114-116.
17. Bowden RG, Wilson RL, Deike E, Gentile M. Fish oil supplementation lowers C-reactive protein levels independent of triglyceride reduction in patients with end-stage renal disease. Nutr Clin Pract. 2009;24(4):508-512.
18. Poulia KA, Panagiotakos DB, Tourlede E, et al. Omega-3 fatty acids supplementation does not affect serum lipids in chronic hemodialysis patients. J Ren Nutr. 2011;21(6):479-484.
19. K/DOQI. Clinical practice guidelines for nutrition in chronic renal failure. K/DOQI, National Kidney Foundation. Am J Kidney Dis. 2000;35(6 Suppl 2):S1-S140.
20. Ruitenberg JJ, Mulder CB, Maino VC, Landay AL, Ghanekar SA. VACUTAINER CPT and Ficoll density gradient separation perform equivalently in maintaining the quality and function of PBMC from HIV seropositive blood samples. BMC Immunol. 2006;7:11.
21. Kalantar-Zadeh K, Kopple JD, Block G, Humphreys MH. A malnutrition-inflammation score is correlated with morbidity and mortality in maintenance hemodialysis patients. Am J Kidney Dis. 2001;38(6):1251-1263.
22. Pisetkul C, Chanchairujira K, Chotipanvittayakul N, Ong-Ajyooth L, Chanchairujira T. Malnutrition-inflammation score associated with atherosclerosis, inflammation and short-term outcome in hemodialysis patients. J Med Assoc Thai. 2010;93 Suppl 1:S147-S156.
23. Ho LC, Wang HH, Chiang CK, Hung KY, Wu KD. Malnutrition- inflammation score independently determined cardiovascular and infection risk in peritoneal dialysis patients. Blood Purif. 2010;30(1): 16-24.
24. Rambod M, Bross R, Zitterkoph J, et al. Association of Malnutrition- Inflammation Score with quality of life and mortality in hemodialysis patients: a 5-year prospective cohort study. Am J Kidney Dis. 2009;53(2):298-309.
25. Friedewald WT, Levy RI, Fredrickson DS. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem. 1972;18(6): 499-502.
26. Moretti HD, Johnson AM, Keeling-Hathaway TJ. Effects of protein supplementation in chronic hemodialysis and peritoneal dialysis patients. J Ren Nutr. 2009;19(4):298-303.
27. Moshage HJ, Janssen JA, Franssen JH, Hafkenscheid JC, Yap SH. Study of the molecular mechanism of decreased liver synthesis of albumin in inflammation. J Clin Invest. 1987;79(6):1635-1641.
28. Kaysen GA, Dubin JA, Muller HG, Rosales L, Levin NW, Mitch WE. Inflammation and reduced albumin synthesis associated with stable decline in serum albumin in hemodialysis patients. Kidney Int. 2004; 65(4):1408-1415.
29. Friedman AN, Fadem SZ. Reassessment of albumin as a nutritional marker in kidney disease. J Am Soc Nephrol. 2010;21(2):223-230.
30. Ando M, Sanaka T, Nihei H. Eicosapentanoic acid reduces plasma levels of remnant lipoproteins and prevents in vivo peroxidation of LDL in dialysis patients. J Am Soc Nephrol. 1999;10(10):2177-2184.
31. Vega GL, Chandalia M, Szczepaniak LS, Grundy SM. Effects of N-3 fatty acids on hepatic triglyceride content in humans. J Investig Med. 2008;56(5):780-785.
32. Hauenschild A, Bretzel RG, Schnell-Kretschmer H, Kloer HU, Hardt PD, Ewald N. Successful treatment of severe hypertriglyceridemia with a formula diet rich in omega-3 fatty acids and medium-chain triglycerides. Ann Nutr Metab. 2010;56(3):170-175.
33. Khajehdehi P. Lipid-lowering effect of polyunsaturated fatty acids in hemodialysis patients. J Ren Nutr. 2000;10(4):191-195.
34. Perunicic-Pekovic GB, Rasic ZR, Pljesa SI, et al. Effect of n-3 fatty acids on nutritional status and inflammatory markers in haemodialysis patients. Nephrology (Carlton). 2007;12(4):331-336.
35. Bouzidi N, Mekki K, Boukaddoum A, Dida N, Kaddous A, Bouchenak M. Effects of omega-3 polyunsaturated fatty-acid supplementation on redox status in chronic renal failure patients with dyslipidemia. J Ren Nutr. 2010;20(5):321-328.
36. Skulas-Ray AC, West SG, Davidson MH, Kris-Etherton PM. Omega-3 fatty acid concentrates in the treatment of moderate hypertriglyceridemia. Expert Opin Pharmacother. 2008;9(7):1237-1248.
37. Saifullah A, Watkins BA, Saha C, Li Y, Moe SM, Friedman AN. Oral fish oil supplementation raises blood omega-3 levels and lowers C-reactive protein in haemodialysis patients - a pilot study. Nephrol Dial Transplant. 2007;22(12):3561-3567.
38. Kooshki A, Taleban FA, Tabibi H, Hedayati M. Effects of marine omega-3 fatty acids on serum systemic and vascular inflammation markers and oxidative stress in hemodialysis patients. Ann Nutr Metab. 2011;58(3):197-202.
39. Raj DS, Boivin MA, Dominic EA, et al. Haemodialysis induces mitochondrial dysfunction and apoptosis. Eur J Clin Invest. 2007;37(12):971-977.
40. Shah VO, Ferguson J, Hunsaker LA, Deck LM, Vander Jagt DL. Cardiac glycosides inhibit LPS-induced activation of pro-inflammatory cytokines in whole blood through and NF-kB-dependent mechanism. Int J Appl Res Nat Prod. 2011;4:11.
41. Szklarek-Kubicka M, Fijalkowska-Morawska J, Zaremba-Drobnik D, Ucinski A, Czekalski S, Nowicki M. Effect of intradialytic intravenous administration of omega-3 fatty acids on nutritional status and inflammatory response in hemodialysis patients: a pilot study. J Ren Nutr. 2009;19(6):487-493.
42. Vernaglione L, Cristofano C, Chimienti S. Omega-3 polyunsaturated fatty acids and proxies of cardiovascular disease in hemodialysis: a prospective cohort study. J Nephrol. 2008;21(1):99-105.
43. Fiedler R, Mall M, Wand C, Osten B. Short-term administration of omega-3 fatty acids in hemodialysis patients with balanced lipid metabolism. J Ren Nutr. 2005;15(2):253-256.
44. Saifullah A, Watkins BA, Saha C, Li Y, Moe SM, Friedman AN. Oral fish oil supplementation raises blood omega-3 levels and lowers C-reactive protein in haemodialysis patients - a pilot study. Nephrol Dial Transplant. 2007;22(12):3561-3567.
45. Rasic-Milutinovic Z, Perunicic G, Pljesa S, et al. Effects of N-3 PUFAs supplementation on insulin resistance and inflammatory biomarkers in hemodialysis patients. Ren Fail. 2007;29(3):321-329.
46. Ewers B, Riserus U, Marckmann P. Effects of unsaturated fat dietary supplements on blood lipids, and on markers of malnutrition and inflammation in hemodialysis patients. J Ren Nutr. 2009;19(5):401-411.